***DUPLICATE PPI/H2RA PROTOCOL:***

***CONCURRENT PROTON PUMP INHIBITOR-H2 RECEPTOR ANTAGONIST THERAPY***

When a patient is receiving concurrent therapy with a PPI and an H2RA, these guidelines would allow the clinical pharmacist to stop one of the agents, provided they are not both ordered by the same prescriber. The reasons for avoiding this duplication are safety-related (the avoidance of adverse events and increased risk of *C. difficile* infection seen from each therapeutic class).

The factors that will be considered in the discontinuation of one of these agents are the following:

* Home medications
* Renal function
* Most recent order
* Possible GI consult
* Disease state
* Ability or inability to tolerate oral medications